Pfizer is exploring the sale of its hospital drugs unit, as the drugmaker, which has been under pressure from activist investor Starboard Value, looks to divest non-core assets, according to three people familiar with the matter.

Pfizer is currently assessing the potential divestiture of its hospital drugs unit, a division mainly focused on antibiotics and sterile injectables used in hospitals and clinics, Reuters reported. The company has engaged Goldman Sachs to solicit initial interest from prospective buyers,

Pfizer (NYSE:PFE) has hired Goldman Sachs to gauge initial buyer interest as part of an attempt to sell its hospital drugs unit, Pfizer Hospital, potentially worth a few billion dollars, Reuters reported Tuesday,